← Open Payments lookup

NPI 1366565004: Open Payments

NPI 1366565004. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.

See the full provider profile for registry, prescribing and billing details.

Industry payments (Sunshine Act)

Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.

$2,971 in 109 payments from 19 companies in 2025. Trend: 2023 $4,429 · 2024 $4,126 · 2025 $2,971

Food & beverage: $2,752Education: $219
CompanyPaymentsAmount
Axsome Therapeutics, Inc.21$477
Vanda Pharmaceuticals Inc.10$421
Teva Pharmaceuticals USA, Inc.6$294
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)5$286
ABBVIE INC.19$282
Otsuka America Pharmaceutical, Inc.9$273
Neurocrine BioSciences, Inc.13$231
Alkermes, Inc.11$183
Tris Pharma Inc2$121
Avadel CNS Pharmaceuticals, LLC1$112

Products named: Auvelity, CAPLYTA, REXULTI, VRAYLAR, INGREZZA, FANAPT, HETLIOZ, ARISTADA.